Beyond CRS & ICANS: Insights Into Delayed Neurotoxicity After BCMA CAR-T Therapy in Myeloma | #EHA26

BCMA-directed CAR-T cell therapies have transformed treatment options for patients with relapsed and refractory multiple myeloma. While cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are well-recognized complications, emerging data are exploring non-ICANS neurotoxicity that may occur after CAR-T treatment.

In this EHA 2026 myeloma highlight, learn about new findings on neurological events following BCMA CAR-T therapy, potential mechanisms, clinical features, and what these insights may mean for monitoring and managing patients receiving cellular therapy.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.